Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 12/20 | 0.44 |
| ▸ | RPS6KB1 | P23443 | 12/20 | 0.44 |
| ▸ | AURKB | Q96GD4 | 9/20 | 0.44 |
| ▸ | INCENP | Q9NQS7 | 9/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.34 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL527440 | 1.00 | AKT1 (0.44) | AKT1RPS6KB1AURKBINCENPKDM4E | |
| SCHEMBL527634 | 0.90 | RPS6KB1 (0.53) | AKT1RPS6KB1AURKBINCENP | |
| SCHEMBL527633 | 0.90 | RPS6KB1 (0.53) | AKT1RPS6KB1AURKBINCENP | |
| SCHEMBL527176 | 0.83 | RPS6KB1 (0.61) | AKT1RPS6KB1AURKBINCENP | |
| SCHEMBL14975120 | 0.81 | AKT1 (0.52) | AKT1RPS6KB1AURKBINCENP | |
| SCHEMBL14975121 | 0.81 | AKT1 (0.52) | AKT1RPS6KB1AURKBINCENP | |
| SCHEMBL14974532 | 0.80 | RPS6KB1 (0.50) | AKT1RPS6KB1AURKBINCENP | |
| SCHEMBL14974536 | 0.80 | RPS6KB1 (0.50) | AKT1RPS6KB1AURKBINCENP | |
| SCHEMBL527173 | 0.80 | RPS6KB1 (0.53) | AKT1RPS6KB1AURKBINCENP | |
| SCHEMBL527172 | 0.80 | RPS6KB1 (0.53) | AKT1RPS6KB1AURKBINCENP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8710044-B2 | Bicyclic azaheterocyclic carboxamides | MERCK PATENT GMBH (DE) | 2014-04-29 | — | — | US | disclosed |
| EP-2598492-A1 | BICYCLIC AZAHETEROCYCLIC CARBOXAMIDES AS INHIBITORS OF THE KINASE P70S6K | Merck Patent GmbH (DE) | 2013-06-05 | — | — | EP | disclosed |
| US-20130137677-A1 | Bicyclic Azaheterocyclic Carboxamides | MERCK PATENT GMBH (DE) | 2013-05-30 | — | — | US | disclosed |
| WO-2012013282-A1 | BICYCLIC AZAHETEROCYCLIC CARBOXAMIDES AS INHIBITORS OF THE KINASE P70S6K | MERCK PATENT GMBH (DE) | 2012-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130137677-A1 | Bicyclic Azaheterocyclic Carboxamides | CCNI, CCNA1, CCNA2 | AKT1 2155/4885RPS6KB1 731/4885AURKB 460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.